paper
review
recent
advanc
made
clinic
use
antivir
agent
respiratori
infect
give
overview
problem
hinder
develop
focus
amantadin
rimantadin
interferon
particular
attent
effect
strategi
use
clinic
use
antivir
agent
respiratori
ill
hamper
fact
multipl
caus
includ
serolog
distinct
virus
repres
major
viru
famili
lj
far
virusspecif
antivir
agent
develop
influenza
virus
amantadin
rimantadin
futur
advanc
field
depend
part
identifi
potent
select
agent
addit
larg
group
virus
caus
rel
small
number
overlap
clinic
syndrom
particular
syndrom
caus
number
differ
virus
convers
particular
viru
caus
number
differ
clinic
syndrom
virus
also
differ
epidemiolog
pattern
togeth
observ
mean
effect
prophylaxi
respiratori
viral
ill
would
requir
broad
spectrum
agent
could
continu
administ
possibl
appear
remot
present
time
altern
effect
intervent
depend
use
narrow
spectrum
agent
conjunct
rapid
specif
viral
diagnosi
one
aspect
virus
share
common
affin
human
respiratori
tract
use
antivir
mean
effect
drug
concentr
must
achiev
site
infect
within
cell
respiratori
epithelium
rais
practic
problem
gain
adequ
deliveri
oral
parenter
administ
antivir
respiratori
mucosa
hand
topic
use
antivir
afford
potenti
achiev
high
region
antivir
concentr
reduc
risk
system
toxic
avoid
unfavor
pharmacolog
associ
system
use
approach
use
sucess
aerosol
ribavirin
intranas
interferon
natur
deliveri
system
critic
variabl
addit
problem
respiratori
viral
infect
selflimit
ill
mean
potenti
antivir
agent
must
high
therapeut
indici
particular
drug
use
prophylaxi
normal
children
adult
fraction
expect
contract
infect
antivir
must
free
signific
side
effect
gener
clinic
use
antivir
agent
respiratori
viral
infect
depend
develop
strategi
effect
safe
longterm
repeat
drug
administr
includ
emerg
drug
resist
virus
addit
strategi
must
also
econom
feasibl
accept
physician
public
season
prophylaxi
effect
use
viral
infect
occur
epidem
short
durat
pattern
classic
shown
influenza
virus
caus
annual
outbreak
last
week
particular
region
mani
virus
includ
respiratori
syncyti
viru
parainfluenza
viru
type
rhinoviru
coronaviru
distinctli
season
pattern
durat
period
activ
associ
attack
rate
occurr
overlap
period
activ
import
variabl
consid
season
prophylaxi
prophylaxi
exposur
person
respiratori
ill
commonli
occur
famili
set
effect
approach
high
rate
secondari
transmiss
epidemiolog
studi
shown
case
rhinoviru
cold
well
influenza
respiratori
syncyti
viru
infect
schoolag
children
frequent
implic
introduc
viru
household
prophylaxi
instutit
popul
hospit
nurs
home
board
school
day
care
center
appropri
document
risk
nosocomi
spread
found
influenza
b
virus
respiratori
syncyti
viru
adenoviru
therapeut
valu
antivir
agent
depend
frequenc
infect
associ
morbid
sinc
use
limit
individu
symptomat
drug
side
effect
accept
particularli
individu
high
risk
seriou
complic
import
target
therapi
includ
influenza
viru
infect
children
adult
respiratori
syncyti
viru
parainfluenza
viru
adenoviru
infect
children
other
rhinoviru
coronaviru
common
caus
infect
high
cumul
burden
morbid
econom
loss
may
associ
import
complic
includ
exacerb
airway
diseas
chronic
lung
diseas
bacteri
infect
ear
sinus
previous
normal
patient
reason
infect
also
appropri
target
treatment
oldest
antivir
compound
use
respiratori
viral
infect
amantadin
analogu
rimantadin
discov
earli
clinic
effect
spectrum
limit
influenza
virus
tabl
show
result
repres
placebocontrol
studi
prophylaxi
influenza
viru
infect
illustr
antivir
agent
use
effect
epidem
diseas
influenza
season
prophylaxi
open
popul
student
oral
amantadin
rimantadin
associ
protect
efficaci
rang
ill
due
laboratoryconfirm
influenza
viru
infect
studi
found
drug
less
effect
prevent
infect
influenza
viru
prevent
ill
may
desir
featur
prophylaxi
sinc
subclin
infect
could
provid
immun
subsequ
infect
sever
studi
attempt
use
amantadin
postexposur
prophylaxi
famili
contact
galbraith
et
al
found
complet
protect
influenz
ill
household
contact
index
case
proven
influenza
infect
followup
studi
found
littl
evid
protect
contact
seroneg
studi
approach
use
rimantadin
current
progress
sever
differ
studi
establish
efficaci
institutionbas
prophylaxi
one
trial
conduct
univers
washington
found
amantadin
highli
effect
prevent
ill
infect
due
influenza
patient
hospit
acut
medic
ward
recent
studi
found
lower
amantadin
dose
highli
protect
larg
group
teenag
boy
hous
english
public
board
school
studi
univers
rochest
found
rimantadin
prophylact
effect
elderli
nurs
home
resid
immun
reduct
clinic
influenza
found
rimantadin
group
compar
placebo
studi
found
addit
effect
appear
exist
protect
amantadin
rimantadin
inactiv
influenza
vaccin
one
impedi
wider
use
amantadin
unit
state
concern
regard
drug
side
effect
initi
point
russian
investig
rimantadin
significantli
lower
potenti
caus
side
effect
administ
dosag
amantadin
studi
conduct
univers
vermont
student
given
amantadin
rimantadin
prophylaxi
dose
mg
per
day
period
week
percent
subject
develop
central
nervou
system
toxic
significantli
higher
amantadin
group
either
rimantadin
placebo
group
toxic
primarili
manifest
insomnia
jitteri
difficulti
concentr
univers
virginia
shortterm
studi
compar
toler
drug
healthi
adult
dose
mg
per
day
day
fraction
amantadin
recipi
develop
central
nervou
system
toxic
increas
wherea
rimantadin
group
differ
significantli
placebo
drug
associ
significantli
higher
rate
gi
side
effect
amantadin
rimantadin
primarili
nausea
upset
stomach
placebo
pharmacokinet
reason
rimantadin
lower
potenti
central
nervou
system
side
effect
appear
relat
differ
plasma
concentr
pharmacokinet
two
drug
tabl
ii
list
combin
result
compar
singledos
pharmacokinet
studi
involv
elderli
age
year
young
age
year
adult
amantadin
readili
absorb
gastrointestin
tract
rapidli
achiev
high
plasma
concentr
wherea
rimantadin
slower
oral
absorpt
achiev
significantli
lower
plasma
concentr
plasma
elimin
halflif
rimantadin
approxim
twice
amantadin
urinari
excret
rimantadin
much
less
amantadin
excret
unchang
urin
urinari
excret
hour
hydroxyl
rimantadin
metabolit
averag
onefifth
dose
differ
plasma
concentr
drug
correl
differ
risk
central
nervou
system
side
effect
also
rais
question
rimantadin
retain
clinic
activ
despit
much
lower
plasma
concentr
amantadin
part
answer
may
lie
vitro
anim
model
observ
rimantadin
somewhat
greater
intrins
antivir
activ
amantadin
importantli
drug
appear
differ
volum
distribut
penetr
respiratori
secret
studi
describ
maximum
measur
nasal
mucu
concentr
period
similar
amantadin
rimantadin
ratio
peak
nasal
mucu
plasma
concentr
higher
rimantadin
vs
p
suggest
rimantadin
may
concentr
respiratori
secret
sinc
mucu
concentr
may
accur
reflect
intracellular
concentr
respiratori
mucosa
plasma
concentr
pharmacokinet
observ
may
provid
part
explan
clinic
efficaci
rimantadin
dose
associ
significantli
lower
plasma
concentr
summari
pharmacolog
differ
drug
confirm
clinic
advantag
rimantadin
respect
compar
efficaci
dose
significantli
lower
potenti
side
effect
broad
spectrum
vitro
antivir
activ
appar
role
resolut
viral
infect
interferon
long
consid
import
candid
prophylaxi
respiratori
viru
infect
work
area
receiv
tremend
boost
recombin
dna
techniqu
success
appli
product
interferon
wide
rang
volunt
experi
conduct
past
year
volunt
studi
studi
gener
use
similar
design
volunt
given
intranas
interferon
spray
drop
form
sever
day
expos
rhinoviru
nasal
challeng
studi
conduct
sever
center
conclus
shown
recombin
interferon
specif
leukocyt
interferon
rifna
provid
protect
experiment
rhinoviru
cold
involv
rang
rhinoviru
serotyp
studi
common
cold
unit
protect
also
observ
human
leukocytederiv
interferon
lymphoblastoid
interferon
recent
recombin
ifn
field
studi
encourag
result
observ
volunt
studi
led
field
trial
design
determin
whether
intranas
interferon
could
protect
natur
respiratori
viru
infect
first
doubleblind
placebocontrol
studi
conduct
charlottesvil
septemb
time
coincid
annual
fall
peak
rhinoviru
activ
recombin
administ
intranas
spray
dose
iu
daili
spray
period
rhinovirus
enteroviru
recov
placebo
subject
upper
respiratori
ill
attack
rate
wherea
none
interferon
group
document
rhinoviru
cold
importantli
rebound
rhinoviru
infect
observ
week
stop
spray
use
howev
number
respiratori
ill
defin
occurr
respiratori
symptom
day
altern
occurr
symptom
consecut
day
significantli
higher
interferon
ill
placebo
group
ill
analysi
show
ill
occur
princip
second
third
week
interferon
administr
larg
due
complaint
nasal
obstruct
recogn
manifest
local
side
effect
interferon
effort
identifi
dose
regimen
would
accept
season
prophylaxi
healthi
adult
investig
univers
michigan
univers
adelaid
conduct
similar
studi
lower
interferon
dose
studi
found
iu
twice
daili
week
provid
approxim
protect
natur
rhinoviru
infect
howev
studi
found
protect
coronaviru
influenza
parainfluenza
viru
infect
importantli
field
studi
use
longterm
administr
abl
clearli
show
benefici
effect
regard
prevent
respiratori
symptom
due
part
observ
onehalf
interferonexpos
adult
develop
nasal
side
effect
sever
week
exposur
toxic
commonli
encount
complaint
nasal
stuffi
bloodting
nasal
mucu
nasal
dryness
occurr
complaint
relat
dose
durat
exposur
examin
symptomat
individu
sign
mucos
friabil
includ
punctat
bleed
site
less
often
ulcer
addit
interferon
recipi
receiv
approxim
iu
per
day
develop
transient
leukopenia
week
use
find
indic
high
intranas
dose
may
associ
system
effect
sever
placebocontrol
studi
conduct
determin
histolog
nasal
mucosa
interferon
exposur
first
toler
studi
healthi
adult
given
dose
iu
per
day
day
fiftyeight
percent
interferon
recipi
none
placebo
group
moder
sever
degre
subepitheli
inflammatori
cell
infiltr
consist
primarili
lymphocyt
affect
interferon
recipi
rebiopsi
week
complet
exposur
biopi
return
normal
indic
histopatholog
chang
revers
followup
studi
immunohistochem
techniqu
use
determin
natur
inflammatori
infiltr
studi
conduct
rifnia
dosag
unit
per
day
found
approxim
onehalf
interferon
recipi
develop
increas
number
subepitheli
tlymphocyt
earli
fourth
day
exposur
prior
symptom
nasal
irrit
clinic
signific
observ
remain
determin
histolog
chang
may
secondari
immunolog
activ
recombin
interferon
link
clinic
intoler
observ
treatment
occurr
local
intoler
longterm
season
prophylaxi
led
explor
altern
strategi
use
intranas
interferon
one
altern
treatment
establish
infect
sever
studi
conduct
experiment
induc
rhinoviru
infect
assess
therapeut
activ
one
trial
univers
virginia
given
nasal
drop
dose
iu
time
per
day
day
begin
hour
infect
proport
viru
posit
day
reduc
interferon
group
compar
placebo
median
durat
viru
shed
reduc
nearli
day
interferon
group
studi
quantit
viru
shed
found
interferon
markedli
reduc
viru
titer
nasal
secret
third
day
administr
compar
placebo
nasal
symptom
score
peak
second
third
day
infect
placebo
group
significantli
lower
interferon
recipi
also
clear
trend
toward
reduc
quantiti
nasal
mucu
product
day
overal
measur
ill
sever
averag
lower
interferon
group
compar
placebo
summari
interferon
administr
late
incub
period
rhinoviru
infect
significantli
modifi
prevent
rhinoviru
cold
studi
need
determin
interferon
treatment
reduc
symptom
transmiss
infect
risk
complic
natur
cold
postexposur
prophylaxi
anoth
logic
strategi
prevent
common
cold
postexposur
prophylaxi
famili
contact
investig
sever
institut
recent
complet
longterm
doubleblind
placebocontrol
studi
determin
use
intranas
interferon
prevent
ill
household
contact
famili
member
respiratori
ill
wherea
low
dose
rifnaa
x
iuday
day
appear
prevent
transmiss
cold
higher
dose
x
iuday
day
significantli
reduc
respiratori
ill
occurr
famili
contact
interferon
also
well
toler
use
manner
evid
cumul
toxic
found
tabl
iii
summar
clinic
applic
antivir
agent
respiratori
viral
infect
influenza
viru
infect
oral
amantadin
rimantadin
effect
use
season
prophylaxi
prophylaxi
institut
popul
drug
well
aerosol
ribavirin
antivir
therapeut
effect
uncompl
influenza
remain
determin
whether
modal
possibl
combin
use
use
treat
sever
influenza
hospit
patient
whether
prevent
develop
complic
high
risk
patient
unfortun
parenter
formul
amantadin
rimantadin
use
critic
ill
patient
aerosol
ribavirin
also
shown
modest
therapeut
effect
influenza
b
viru
infect
howev
major
need
exist
antivir
activ
influenza
b
viru
use
outpati
basi
control
clinic
trial
shown
aerosol
ribavirin
therapi
improv
arteri
oxygen
modifi
sever
respiratori
syncyti
viru
bronchiol
pneumonia
role
treat
lifethreaten
diseas
modifi
longterm
sequela
rsv
infect
unknown
present
time
specif
antivir
agent
need
outpati
use
prevent
treat
rsv
infect
final
decad
work
sinc
origin
observ
intranas
interferon
could
prevent
experiment
rhinoviru
infect
recent
studi
establish
intranas
effect
postexposur
prophylaxi
rhinoviru
cold
famili
strategi
need
studi
regard
prevent
infect
complic
high
risk
patient
remain
determin
whether
intranas
interferon
therapeut
activ
establish
cold
